Literature DB >> 12226029

Technical and prognostic outcomes of double-balloon pericardiotomy for large malignancy-related pericardial effusions.

Huang-Joe Wang1, Kwan-Lih Hsu, Fu-Tien Chiang, Chuen-Den Tseng, Yung-Zu Tseng, Chiau-Suong Liau.   

Abstract

OBJECTIVE: To investigate both the use of immediate or elective double-balloon pericardiotomy (DBP) in patients with a large amount of malignancy-related pericardial effusion, and the prognosis of this subgroup.
DESIGN: Observational study after DBP intervention.
SETTING: Tertiary referral center. PATIENTS AND
INTERVENTIONS: Fifty patients with malignancy, mainly lung and breast cancer, who were admitted to our critical care unit with a large amount of pericardial effusion. All received echocardiographic-guided pericardiocentesis. Group 1 consisted of 12 patients (24%) who received immediate DBP, and group 2 consisted of 38 patients (76%) who received delayed DBP 2.5 +/- 1.7 days later (mean +/- SD) after emergency pericardiocentesis with pigtail catheter drainage. MEASUREMENTS: After the procedure, and at 1 month, 3 months, and 6 months, echocardiography and chest radiography were performed to check for pneumothorax, pericardial effusion reaccumulation, or the appearance of pleural effusion after pigtail catheter removal. MAIN
RESULTS: The procedure was successful and without recurrence in 44 patients (88%). Procedural complications were fever in 4 patients (33%) and 10 patients (26%) in group 1 and group 2, respectively (p = 0.72), and mild pneumothorax in 2 patients (17%) and 1 patient (3%) in group 1 and group 2, respectively (p = 0.14). Fifty percent of the patients died within 4 months, while 25% survived to 11 months. High serum calcium, a low albumin/globulin ratio, and positive results on pericardial effusion cytology were poor prognostic factors for long-term survival.
CONCLUSION: Both immediate and delayed DBP are a safe and effective method of relieving large pericardial effusions in patients with cancer. Successful DBP without recurrence of pericardial effusion was achieved in 88% of all patients. Survival was related to the extent of the disease.

Entities:  

Mesh:

Year:  2002        PMID: 12226029     DOI: 10.1378/chest.122.3.893

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Diagnosis and management of pericardial effusion.

Authors:  Jaume Sagristà-Sauleda; Axel Sarrias Mercé; Jordi Soler-Soler
Journal:  World J Cardiol       Date:  2011-05-26

2.  Percutaneous treatment in patients presenting with malignant cardiac tamponade.

Authors:  P Y Marcy; P Y Bondiau; P Brunner
Journal:  Eur Radiol       Date:  2005-01-21       Impact factor: 5.315

3.  Neoplastic pericardial disease: Old and current strategies for diagnosis and management.

Authors:  Chiara Lestuzzi
Journal:  World J Cardiol       Date:  2010-09-26

4.  Risk factors affecting the survival rate in patients with symptomatic pericardial effusion undergoing surgical intervention.

Authors:  Seyed Mohsen Mirhosseini; Mohammad Fakhri; Amirhossein Mozaffary; Mojtaba Lotfaliany; Neda Behzadnia; Zahra Ansari Aval; Seyed Mohammad Saeed Ghiasi; Mohammad Reza Boloursaz; Mohammad Reza Masjedi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-12-18

5.  Differential Impact of Constrictive Physiology after Pericardiocentesis in Malignancy Patients with Pericardial Effusion.

Authors:  In-Jeong Cho; Hyuk-Jae Chang; Hyemoon Chung; Sang-Eun Lee; Chi Young Shim; Geu-Ru Hong; Jong-Won Ha; Namsik Chung
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

6.  Performance, pain, and quality of life on use of central venous catheter for management of pericardial effusions in patients undergoing coronary artery bypass graft surgery.

Authors:  Kamran Ghods; Mohammad Reza Razavi; Mohammad Forozeshfard
Journal:  J Pain Res       Date:  2016-10-31       Impact factor: 3.133

7.  A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).

Authors:  H Kunitoh; T Tamura; T Shibata; M Imai; Y Nishiwaki; M Nishio; A Yokoyama; K Watanabe; K Noda; N Saijo
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.